Results 181 to 190 of about 186,361 (263)

Refractory Eczema as a Presenting Feature of Common Variable Immunodeficiency

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Common variable immunodeficiency (CVID) is the most prevalent symptomatic inborn error of immunity (IEI) in adults. It presents with recurrent infections and non‐infectious complications, including autoimmunity, lymphoproliferation and dermatitis.
Mercedes Sanchez‐Diaz   +2 more
wiley   +1 more source

Bevacizumab‐Associated Eczema Herpeticum in Metastatic Ovarian Carcinoma: A Case Report

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Eczema herpeticum (EH) is a rare but potentially life‐threatening cutaneous infection caused by herpes simplex virus (HSV), classically associated with atopic dermatitis. Its occurrence in oncology patients receiving anti‐angiogenic targeted therapy and cytotoxic chemotherapy is exceedingly uncommon.
Mandeep Dutta Joshi   +6 more
wiley   +1 more source

Triggering Receptor Expressed on Myeloid Cells‐2 Regulates Innate Lymphoid Cell Levels in Bleomycin‐Induced Pulmonary Fibrosis

open access: yesThe Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Idiopathic pulmonary fibrosis, a pathological change causing poor outcomes, is not reversible despite current antifibrotic therapy. Emerging evidence suggests that innate lymphoid cells (ILCs) mediate lung inflammation and fibrosis after stimulation by endogenous factors.
Hsiao‐Chin Shen   +7 more
wiley   +1 more source

Bilateral Ophthalmoplegia After Neoadjuvant Pembrolizumab for Oral Cavity Squamous Cell Carcinoma

open access: yesThe Laryngoscope, EarlyView.
The role of immune checkpoint inhibition (ICI) therapy in the treatment of head and neck squamous cell carcinoma (HNSCC) is expanding with increased utilization of neoadjuvant and adjuvant pembrolizumab in the setting of locally advanced disease. This report describes the presentation and management of the first known case of pembrolizumab‐induced ...
Leonard E. Estephan   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy